Siren LLC’s Janux Therapeutics JANX Stock Holding History

Siren LLC’s Portfolio JANX Stock Details JANX Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2025 Q1	–	Sell	-175,000	Closed	-$9.37M	–	128
2024 Q4	$9.37M	Buy	+175,000	New	+$9.26M	0.41%	48

Other funds holding JANX

RA Capital Management Boston, Massachusetts $11.5B AUM 168.77% 1-Year Est. Return

Fidelity Investments Boston, Massachusetts $2.3T AUM 54.33% 1-Year Est. Return

Janus Henderson Group London $209B AUM 37.72% 1-Year Est. Return

Adage Capital Partners Boston, Massachusetts $71.3B AUM 56.8% 1-Year Est. Return

Paradigm Biocapital Advisors New York $5.34B AUM 380.18% 1-Year Est. Return

BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return

Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return

CAM

Cormorant Asset Management Boston, Massachusetts $1.95B AUM 773.9% 1-Year Est. Return

Logos Global Management San Francisco, California $2.32B AUM 536.01% 1-Year Est. Return

EcoR1 Capital San Francisco, California $2.06B AUM 215.32% 1-Year Est. Return

Siren LLC's JANX Position: Q1 2025 in Review

Siren LLC sold out of Janux Therapeutics (JANX) in Q1 2025, closing a stake of 175,000 shares — an estimated $9.37M sold.

Siren LLC first reported a position in JANX in Q4 2024 and held it in 1 quarter. The position peaked at $9.37M in Q4 2024. 181 funds tracked by Wall St. Rank hold JANX as of Q1 2025.

Siren LLC reported no remaining Janux Therapeutics position as of Q1 2025 after selling out during the quarter.
Siren LLC sold 175,000 Janux Therapeutics shares in Q1 2025, an estimated $9.37M.
Siren LLC first reported a position in Janux Therapeutics in Q4 2024 and held it in 1 quarter.
Siren LLC's Janux Therapeutics position peaked at $9.37M in Q4 2024.
181 funds tracked by Wall St. Rank held Janux Therapeutics as of Q1 2025.

Based on Siren LLC's 13F filing for Q1 2025, filed 14 May 2025.